ESC 365 - Clinical implications for post-ACS patients

Open Access

Clinical implications for post-ACS patients

Session: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Topic: Treatment

Speaker: Doctor S. Goodman (Toronto, CA)

Sponsored by Sanofi and Regeneron

Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

1 presentation

0 follower

6 more presentations in this session

Welcome and introduction - Highlights from the latest ODYSSEY OUTCOMES data

Speaker: Professor A. Zeiher (Frankfurt, DE)

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels

Speaker: Professor P. Steg (Paris, FR)

Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes

Speaker: Professor K. Ray (London, GB)

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data

Speaker: Professor C. Cannon (Boston, US)

Roundtable: learnings in practice

Speaker: Professor P. Steg (Paris, FR) Professor A. Zeiher (Frankfurt, DE)

Access the full session

Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Speakers: Doctor S. Goodman, Professor A. Zeiher, Professor P. Steg, Professor K. Ray, Professor C. Cannon...

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by